1932043-29-2

Usage

Uses

Used in Pharmaceutical Industry:
C₁₂H₁₉NO₃ is used as a key intermediate in the synthesis of Azabicyclohexane derivatives, which act as muscarinic M1 and M4 agonists. These agonists are of significant interest in the development of drugs targeting the muscarinic receptors, which are involved in various physiological functions, including cognitive processes, memory, and the regulation of heart rate.
In the pharmaceutical industry, the development of muscarinic agonists is crucial for the treatment of various disorders, such as Alzheimer's disease, where the stimulation of M1 receptors can improve cognitive function. Additionally, M4 agonists have potential applications in the treatment of schizophrenia and other psychiatric disorders, as well as in the management of overactive bladder conditions.
Furthermore, C₁₂H₁₉NO₃ contributes to the advancement of drug discovery and development by providing a foundation for the synthesis of novel and more effective muscarinic agonists. This can lead to the creation of safer and more targeted therapies for a wide range of medical conditions.

Upstream product

• 13684-28-1 2-hydroxy-4-nitro-benzoic acid methyl ester 
• 4136-97-4 methyl 4-aminosalicylate 
• 930-68-7 cyclohexenone 
• 867144-27-2 (1S,4S)-2-(4-methoxyphenyl)-2-azabicyclo[2.2.2]octan-5-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 750634-07-2 exo-5-hydroxy-2-azabicyclo-[2.2.2]octan-3-one 
• 794468-38-5 2-aza-bicyclo[2.2.2]octan-5-ol 
• 2597-56-0 4-nitro-o-anisic acid 
• 619-19-2 2-hydroxy-4-nitrobenzoic acid 
• 750634-09-4 tert-butyl 5-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate 

Relevant academic research and scientific papers

Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist

A class of novel pyrimidine derivatives bearing diverse conformationally restricted azabicyclic ether/amine were designed, synthesized and evaluated for their GPR119 agonist activities against type 2 diabetes. Most compounds exhibited superior hEC50

Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists

Compounds having the formula (I), Ar—(F)(E)-(CR3R4)—(CHR5)m-(T)-(Q)-Ar1, are useful as CCR-3 receptor antagonists, wherein T is a bridged heterocyclyl group having one N atom and a bridge of one to two bridgehead carbon atoms; Ar and Ar1 are aryl or heteroaryl; F is alkylene, alkenylene, or a bond; E is —C(═O)N(R10)—, —SO2N(R10)—, —N(R11)C(═O)N(R10O)—, —N(R11)SO2N(R10)—, —N(R11)C(═S)N(R10)—, —N(R11)C(═O)—, —N(R11)SO2—, —N(R12)C(═O)CH(R13)—, or CH(R13)C(═O)N(R12)—; Q is —C(═O)— or C1-2alkylene; and R3, R4, R5, R9, R10, R11, R12, and R13 are defined as set forth in the specification.

Design and synthesis of novel CCR3 antagonists

As part of our investigation into the development of potent CCR3 antagonists, a series of piperidine analogues was designed and prepared. Exploration of the piperidine core examined both the basicity and the location of a nitrogen, as well as conformational variants. The bicyclo-piperidine 24c was found to be the most potent inhibitor of CCR3 with an IC50 of 0.0082 μM in the binding assay and 0.0024 μM in the chemotaxis assay.